Glycosphingolipids as potential diagnostic markers and/or antigens in neurological disorders

Neurochemical Research

Volumn 22, Issue 8, 1997, Pages 1071-1083

  Fredman, Pam ^a,b   Lekman, Annika ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmune disease; Demyelination; Gangliosides; Glycosphingolipids; Neurodegeneration; Neuropathy

Indexed keywords

ANTIBODY; GLYCOSPHINGOLIPID;

ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; AUTOIMMUNITY; CEREBROSPINAL FLUID ANALYSIS; DEMYELINATION; DEVELOPMENTAL DISORDER; DIAGNOSIS; DIAGNOSTIC VALUE; GLIOSIS; GUILLAIN BARRE SYNDROME; HUMAN; LIPOGENESIS; MOTOR NEUROPATHY; NERVE CELL LESION; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ANIMALS; ANTIGENS; AUTOANTIBODIES; GANGLIOSIDES; GLYCOSPHINGOLIPIDS; HUMANS; NERVOUS SYSTEM DISEASES; SPHINGOLIPIDS;

EID: 0030755564     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022495430583     Document Type: Article

References (97)

1. Hakomori S.-I., and Igarashi Y. 1995. Functional role of glycosphingolipids in cell recognition and signalling. J Biochem. 188: 1091-1103.
2. van der Bijl, P., Lopes-Cardozo, M., and van Meer, G. 1996. Sorting of newly synthesized galactosphingolipids to the two surface domains of epithelial cells. J Cell Biology. 132:813-821.
3. Suzuki, K. 1965. The pattern of mammalian brain gangliosides - III regional and developmental changes.
4. Svennerholm, L., Boström, K., Fredman, P., Månsson, J.-E., Rosengren, B., and Rynmark, B.-M. 1989. Human brain ganglioside: developmental changes from early fetal stage to advanced age. Biochim. Biophys. Acta. 1005:109-117.
5. Svennerholm, L. Boström, K., Fredman, P., Jungbjer, B., Lekman, A., Månsson, J.-E., and Rynmark, B.-M. 1994. Gangliosides and allied glycosphingolipids in human peripheral nerve. Biochim. Biophys. Acta. 1214:115-123.
6. Hansson, H.-A., Holmgren, J., and Svennerholm, L. 1977. Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. Proc. Natl. Acad. Sci. (USA). 74:3782-3786.
7. Kotani, M., Kawashima, I., Ozawa, H., Terashima, T., and Tai, T. 1993. Differential distribution of major gangliosides in rat central nervous system detected by specific monoclonal antibodies. Glycobiology. 3:137-146.
8. Kawai, K., Kuroda, S., Watarai, S., Takahashi, H., and Ikuta, F. 1994. Occurrence of GD3 ganglioside in reactive astrocytes - an immunocytochemical study in the rat brain. Neurosci. Lett. 174: 225-227.
9. Fredman, P. 1994. Gangliosides associated with primary brain tumors and their expression in cell lines established from these tumors. Brain Res. 101:225-240.
10. + cells in the developing and adult rat cerebellum belong to the microglial lineage rather than to the oligodendrocyte lineage. Glia. 13:13-26.
11. Fredman, P., Wikstrand, C. J., Månsson, J.-E., Bigner, S. H., Rasheed, A., Svennerholm, L., and Bigner, D. D. 1996. In vivo growth of the human glioma cell line suppress the expression of ganglioside GM2 and favour the expression of the human glioma associated 3′-isoLM1 and 3′6′-isoLD1. Glycoconjugate J. 13:391-399.
12. Buschard K, K. Josefsen, T. Horn, K. Aaen, H. Persson, and P. Fredman. 1996. Presence of sulphatide (3′-sulphogalactosylceramide) in pericytes in the choroid layer of the eye: sharing of this glycolipid antigen with islets of Langerhans. Diabetologia. 39: 658-666.
13. Coteze, T., Fujita, N., Dupree, J., Shi, R., Blight, A., Suzuki, K., Suzuki, K., and Popko, B. 1996. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 86:1-20.
14. Ledeen, R., and Yu, R. 1972. Gangliosides of CSF and plasma: their relation to the nervous system. Adv. Exp. Med. Biol. 19:77-93.
15. Nagai, Y., Kanfer, J. N., and Tourtellotte, W. W. 1973. Preliminary observations of gangliosides of normal and multiple sclerosis cerebrospinal fluid. Neurology. 23:945-948.
16. Davidsson, P., Fredman, P., and Svennerholm, L. 1989. Gangliosides and sulphatide in human cerebrospinal fluid: Quantitation with immunoaffinity techniques. J. Chromatogr. 496:279-289.
17. Doljanski, F., and Kapeller, M. 1976. Cell surface shedding: the phenomenon and its possible significance. J. Theor. Biol. 62:253-270.
18. Pilz, H. 1970. Die Lipide des normalen und pathologished Liquor cerebrospinalis. Springer-Verlag, Berlin-Heidelberg-New York.
19. Tibbling, G., Link, H., and Öhman, S. 1977. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. J. Clin. Lab. Invest. 37:385-390.
20. Fredman, P., Wallin, A., Blennow, K., Davidsson, P., Gottfries, C. G., and Svennerholm, L. 1992. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta. Neurol. Scand. 85:103-106.
21. Portoukalian, J., Zwingelstein, G., Abdul-Malak, N., and Doré, J.-F. 1978. Alteration of gangliosides in plasma and red cells of human bearing melanoma tumors. Biochem. Biophys. Res. Commun. 85:916-920.
22. Senn, H.-J., Orth, M., Fitzke, E., Wieland, H., and Gerok, W. 1989. Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. Eur. J. Biochem. 181:657-662.
23. Håkansson, L., Fredman, P., and Svennerholm, L. 1985. Gangliosides in serum immune complexes from tumor-bearing patients. J. Biochem. 98:843-849.
24. Trbojevic-Cepe, M., Kracun, I., Jusic, A., and Pavlicek, I. 1991. Gangliosides of human cerebrospinal fluid in various neurologic diseases. J. Neurol. Sci. 105:192-199.
25. Blennow, K., Davidsson, P., Wallin, A., Fredman, P., Gottfries, C.-G., Karlsson, I., Månsson, J.-E., and Svennerholm, L. 1991. Gangliosides in cerebrospinal fluid in 'Probable Alzheimers's disease'. Arch. Neurol. 48:1032-1035.
26. Davidsson, P., Fredman, P., Månsson J.-E., and Svennerholm, L. 1991. Determination of gangliosides and sulfatide in human cerebrospinal fluid with a microimmunoaffinity technique. Clin. Chim. Acta. 197:105-116.
27. Hirabayashi, Y., Koketsu, K., Higashi, H., Suzuki, Y., Matsumoto, M., Sugimoto, M., and Ogawa, T. 1986. Sensitive enzyme-immunostaining and densitometric determination of ganglio-series gangliosides on thin-layer plate: pmol detection of gangliosides in cerebrospinal fluid. Biochim. Biophys. Acta. 876:178-182.
28. Yamanaka, T., Hirabayashi, Y., Koketsu, K., Higashi, H., and Matsumoto, M. 1986. Highly sensitive analysis of gangliosides in human cerebrospinal fluid with neurological diseases. J. Exp. Med. 57:131-135.
29. Svennerholm, L. 1964. The distribution of lipids in the human nervous system. I. Analytical procedure. Lipids of fetal and newborn brain. J. Neurochem. 11:839-853.
30. Yusuf, H. K., Merat, A., and Dickerson, J. W. T. 1977. Effect of development on the gangliosides of human brain. J. Neurochem. 28:1299-1304.
31. Tettamanti, G. 1971. Brain gangliosides in development. Adv. Exper. Med. Biol. 13:75-89.
32. Vanier, M., Holm, M., Ohman, R., and Svennerholm, L. 1971. Developmental profiles of gangliosides in human and rat brain. J. Neurochem. 18:581-592.
33. Goldman, J. E., Hirano, M., Yu, R. K., and Seyfried, T. N. 1984. GD3 ganglioside is a glycolipid characteristic of immature neuroectoderman cells. J. Neurochem. 7:179-192.
34. Goldman, J. E., and Vaysse, P. J.-J. 1991. Tracing glial lineages in the mammalian forebrain. Glia. 4:149-156.
35. Skaper, S. D., and Varon, S. 1985. Ganglioside GM1 overcomes serum inhibition of neuritic outgrowth. Int. J. Devel. Neurosc. 3: 187-198.
36. Schengrund, C.-A. 1990. The role(s) of gangliosides in neuronal differentiation and repair: A perspective. Brain Research Bulletin. 24:131-141.
37. Yates, A. J. 1986. Gangliosides in the nervous system during development and regeneration. Neurochem. Pathol. 5:309-329.
38. Izumi, T., Ogawa, T., Koizumi, H., and Fukuyama, Y. 1993. Normal developmental profiles of CSF gangliotetraose-series gangliosides from neonatal period to adolescence. Pediatr. Neurol. 9: 297-300.
39. Lekman, A., Skjeldal, O., Sponheim, O., and Svennerholm, L. 1995. Gangliosides in children with autism. Acta. Pœdiatr. 84: 787-790.
40. Nordin, V., Lekman, A., Johansson, M., Fredman, P., and Gillberg, C. 1996. Gangliosides in cerebrospinal fluid in children with autism spectrum disorders. Submitted.
41. Izumi, T., Ogawa, T., Koizumi, H., and Fukuyama, Y. 1993. Low levels of CSF gangliotetraose-series gangliosides in West syndrome: implication of brain maturation disturbance. Padiatr. Neurol. 9:293-6.
42. Sandhoff, K., and Conzelmann, E. 1984. The biochemical basis of gangliosidosis. Neuropediatrics. 15:85-92.
43. Pullarkart, R. K., Reha, H., and Beratis, N. G. 1981. Accumulation of GM2 ganglioside in cerebrospinal fluid of a patient with the variant AB of infantile GM2 gangliosidosis. Pediatrics. 68:106-108.
44. Kotagal, S., Wenger, D. A., Gomez, C., and Horenstein, S. 1986. AB variant GM2 gangliosidosis: cerebrospinal fluid and neuropathological characteristics. Neurology. 36:438-440.
45. Fredman, P., Blennow, K., Wallin, A., Gottfries, C. G., and Svennerholm, L. 1993. Gangliosides and sulfatide in CSF - Biological markers for Alzheimer's disease and vascular dementia. Pages 400-403, in Felgenhauer, K., Holzgraefe, M., and Prange, H. W. (eds), CNS Barriers and Modern CSF Diagnostics, VCH Weinheim, New York.
46. Gisslén, M., Fredman, P., Norkrans, G., and Hagberg, L. 1996. Elevated cerebrospinal fluid sulfatide concentrations as a sign of increased metabolic turnover of myelin in HIV type I infection. AIDS. Res. Human Retrovir. 12:149-155.
47. Gisslén, M., Hagberg, L., Norkrans, G., Lekman, A., and Fredman, P. 1996. Increased cerebrospinal fluid ganglioside GM1 concentrations indicating neuronal involvement in all stages of HIV-1 infection. J. Neurovirol. In press.
48. Lekman, A., and Fredman, P. 1996. A new procedure to determine ganglioside GD3, a potential glial cell activation marker in cerebrospinal fluid. In preparation.
49. Tarvonen-Schröder, S., Blennow, K., Lekman, A., Fredman, P., Räihä, I., and Sourander, L. 1996. Gangliosides and sulfatide in cerebrospinal fluid in leukoaraiosis. J. Neurotrans. In press.
50. Kellaway, P., Hrachovy, R. A., Frost, J. D., Jr., and Zion, T. 1979. Precise characterization and quantification of infantile spasms. Ann. Neurol. 6:214-218.
51. Gomez, M. R., and Klass, D. W. 1983. Epilepsies of infancy and childhood. Ann. Neurol. 13:113-124.
52. Lekman, A., Hagberg, B., and Svennerholm, L. 1996. Gangliosides for early differential diagnosis between Rett syndrome and infantile neuronal ceroid lipofuscinosis. In preparation.
53. Gleeson, P. A. 1994. Glycoconjugates in autoimmunity. Biochim. Biophys. Acta. 1197:237-255.
54. Ilyas, A. A., Quarles, R. H., MacIntosh, T. D., Dobersen, M. J., Dalakas, M. C., and Bray, R. O. 1984. IgM in a human neuropathy related to paraproteinaemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc. Natl. Acad. Sci. 81:1225-1229.
55. Chou, D. K. H., Ilyas, A. A., Evans, J. E., Costello, C., Quarles, R. H., and Jungalwala, F. B. 1986. Structure of sulfated-glucoronyl glycolipids in the nervous system reacting with HNK-1 antibody and some IgM paraproteins in neuropathy. J. Biol. Chem. 261:11717-117725.
56. Fredman, P., Lycke, J., Andersen, O., Vrethem, M., Ernerudh, J., and Svennerholm L. 1993. Peripheral neuropathy associated with monoclonal IgM antibody glycolipids with a terminal glucuronyl-3-sulfate epitope. J. Neurology 240:381-387.
57. Quarles, R. H. 1984. Myelin-associated glycoprotein in development and disease. Developmental Neurosci. 6:285-303.
58. Hughes, R. A. C. 1994. Inflammatory neuropathies. Baillière's Clinical Neurology, 3:45-72.
59. Willison, H. J. 1994. Antiglycolipid antibodies in peripheral neuropathy: fact or fiction. J. Neurol. Neurosurg. Psychiatry. 57: 1303-1307.
60. O'Leary, C., and Willison, H. J. 1995. Immunological investigation. Curr Opinion in Neurology. 8:349-353.
61. Saida, T., Saida, K., Lisak, R. P., Brown, M. J., Silberberg, D. H., and Asbury A. K. 1982. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann. Neurol. 11:69-75.
62. Hays, A. P., Latov, N., Takatsu, M., and Sherman, W. H. 1987. Experimental demyelination of nerve induced by serum from patients with neuropathy and an anti-MAG IgM-M protein. Neurology. 37:242-56.
63. Tatum, A. H. 1993. Experimental paraproteinaemic neuropathy, demyelination by passive transfer of human IgM anti-myelin associated glycoprotein antibody. Ann. Neurol. 33:502-506.
64. Svennerholm, L., and Fredman, P. 1990. Antibody detection in Guillain-Barré syndrome. Ann. Neurol. 27:36-40.
65. Fredman, P., Vedeler, C. A., Nyland, H., Aarli, J. A., and Svennerholm, L. 1991. Antibodies in sera from patients with inflammatory demyelinating polyradiculo neuropathy react with ganglioside LM1 and sulfatide of peripheral nerve myelin. J. Neurol. 238:75-79.
66. Kaldor, J., and Speed, B. R. 1984. Guillain Barré syndrome and Campylobacter jejuni: a serological study. Br Med J. 288:1867-1870.
67. Yuki, N., Yoshino, H., Sato, S., and Miyatake T. 1990. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40:1900-1902.
68. Ho, T. W., Mishu, B., Li, C. Y., Gao, C. Y., Cornblath, D. R., Griffin, J. W., Asbury, A. K., Blaser, M. J., and McKahnn, G. 1995. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 118:597-605.
69. Chiba, A., Kusunoki, S., Shimizu, T., and Kanazawa, I. 1992. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrom. Ann Neurol. 31:677-679.
70. Willison, H. J., Veitch, J., Paterson, G., and Kennedy, P. G. E. 1993. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J. Neurol Neurosurg. Psychiat. 56:204-206.
71. Dalakas, M. C., and Quarles, R. H. 1996. Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipid the responsible antigens. Ann. Neurol. 39:419-422.
72. Buschard, K., Josefsen, K., Horn, T., and Fredman, P. 1993. Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet. 342:840.
73. Pestronk, A., Adams, R. N., Kuncl, R. W., Drachman, D. B., Clawson, L. L., and Cornblath, D. R. 1989. Differential effects of prednisone and cyclophosphamide on autoantibodies in human neuromucular disorders. Neurology. 39:628-633.
74. Chaudry, V., Corse, A. M., Corblath, D. R., Kuncl, R. W., Drachman, D. B., Freimer, M. L., Miller, R. G., and Griffin, J. W. 1993. Multifocal motor neuropathy: response to human immune globulin. Ann. Neurol. 33:237-242.
75. Sadiq, S. A., Thomas, F. P., and Kilidireas, K. 1990. The spectrum of neurological disease associated with anti-GM1 antibodies. Neurology. 40:1067-1072.
76. Kornberg, A. J., and Pestronk, A. 1994. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve. 17:100-104.
77. Weller, M., Stevens, A., Sommer, N., Dichgans, J., Kappler, B., and Wiethölter, H. 1992. Ganglioside antibodies: a lack of diagnostic specificity and clinical utility? J Neurol. 239:455-459.
78. Parry, G. J. 1994. Antiganglioside antibodies do not necessarily play a role in multifocal neuropathy. Muscle Nerve. 17:97-99.
79. Taylor, B. V., Gross, L., and Windebank, A. J. 1996. The sensitivity and specificity of anti-GM1 antibody testing. Neurology. 47: 951-955.
80. Stevens, A., Weller, M., and Wiethölter, H. 1993. A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psych. 56:361-364.
81. Iniguez, C., Jinénez-Escrig, A., Gobernado, J. N., Nocito, M., and Gonzalez-Porque, P. 1995. Antiganglioside antibodie in the CSF of patients with motor neuron diseases and Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 58:519-520.
82. de Gasperi, R., Sosa, M. A. G., Patarca, R., Battistini, S., Lamoreux, M. R., Ragha van, S., Kowall, N. W., Harrnington Smith, K., Pletcher M.-A., and Kolodny, E. H. 1996. Intrathecal synthesis of anti-sulfatide IgG is associated with peripheral nerve disease in acquired immunodeficiency syndrome. Aids Res. Hum. Retrovirus. 12:205-209.
83. Marcus, D. M., Latov, N., Hsi, B. P., and Gillard, B. K. 1989. Measurement and significance of antibodies against GM1 ganglioside. J Neuroimmunol. 25:255-259.
84. Zielasek, J., Ritter, G., Magi, S., Hartung, H. P., and Toyka, K. V. 1994. A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1, J. Neurol. 241:475-480.
85. Ravindrath, M. H., Ravindrath, R. M, H., Morton, D. L., and Graves M. C. 1994. Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. J. Neuroimmunol. Meth. 169:257-272.
86. Gregson, N. A., Koblar, S., and Hughes, R. A. C. 1993. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and clinical features. QJ Med. 86:111-117.
87. Haas, D. C., and Tatum, A. H. 1988. Plasmapheresis alleviate neuropathy accompanying IgM anti-MAG paraproteinemia. Ann. Neurol. 23:394-396.
88. Harvey, G. K., Toyka, K. V., Zielasek, J., Kieffer, R., Simmons, C., and Hartung, H. P. 1995. Failure of anti-GM1 IgG and IgM to induce conduction block following intraneural transfer. MuscleNerve. 18:388-394.
89. + currents in isolated rat myelin fibers. Ann. Neurol. 37: 436-442.
90. Ganser, A. L., Kirschner, D. A., and Willinger, M. 1983. Ganglioside localization on myelinated nerve fibres by cholera toxin binding. J. Neurocytology. 12:921-938.
91. Nardelli, E., Anzini, P., Moretto, G., Rizzuto, N., and Steck, A. J. 1994. Pattern of nervous tissue immunostaining by human antiglycolipid antibodies. J. Neurol. Sci. 122:220-227.
92. Molander, M., Berthold, C.-H., Persson, H., Andersson, K., and Fredman, P. 1997. Monosialoganglioside (GM1) immunofluorescence in rat spinal roots studied with a monoclonal antibody. J Neurocytology, accepted.
93. Ilyas, A. A., Mithen, F. A., Dalakas, M. C., Chen, Z.-W., and Cook, S. D. 1992. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol. Sci. 107:111-121.
94. Chou, D. K., and Jungalwala, F. B. 1993. N-acetylglucosaminyl-transferas regulates the expression of neolactoglycolipids including sulfoglucuronylglycolipids in the developing nervous system. J Biol. Chem. 268:21727-21733.
95. Pestronk, A. 1991. Invited review, motor neuropathies, motor neuron disorders and anti-glycolipid antibodies. Muscle Nerve. 14: 927-936.
96. Morell, P., Quarles, R. H., and Norton, W. T. 1994. Myelin formation structure, and biochemistry. In Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. G. J. Siegel, B. W. Agranoff, R. W. Albers, and P. B. Molinoff, eds (New York: Raven Press), pp 117-143.
97. Nair, S. M., Prasadarao, N., Tobef, S. A., and Jungawala, F. B. 1993. Rostrocaudal expression of antibody HNK-1-reactive glycolipid in mouse cerebellum relationship to development compartments and leaner mutation. J. Comp. Neurol. 332:282-292.